期刊文献+

新型双功能螯合剂DOTA及其衍生物在金属核素标记中的应用进展 被引量:1

Application of new bifunctional chelator DOTA and its derivatives in the metal radionuclide labeled compounds
原文传递
导出
摘要 DOTA及其衍生物是应用最为广泛的新型双功能螯合剂之一。DOTA及其衍生物不仅具有成熟的合成工艺路线,还具有良好的配位和螯合能力,DOTA-多肽分子探针作为MRI对比剂、核素靶向显像剂和放射性药物在生物医学领域被广泛应用。笔者对DOTA双功能螯合剂的种类、DOTA-多肽标记前体的合成和DOTA一多肽金属配合物的应用进行综述。 DOTA and its derivatives are most widely used novel bifunctional chelators. They have not only mature synthesis route, but also good coordination and chelating ability. Therefore, DOTA metal complexes of DOTA-peptide conjugates are increasingly used as MRI contrast agents, radionuclide targeted imaging agents and therapeutic radiopharmaceuticals in the biomedical field. This review covers the bifunctional derivatives of DOTA, the synthesis of DOTA-peptide conjugates, and the applications of DOTA-pep-tide conjugate metal complexes.
出处 《中华核医学与分子影像杂志》 CAS 北大核心 2016年第4期371-374,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金(21401084) 无锡市医院管理中心项目(YGZXM14014)
关键词 DOTA 类似物和衍生物 同位素标记 金属 发展趋势 DOTA Analogs & derivatives Isotope labeling Metals Trends
  • 相关文献

参考文献32

  • 1Mohsin H, Jia F, Bryan JN, et al. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149pm, 166Ho, and 177Lu[ J]. Bioconjug Chem, 2001, 22 (12): 2444-2452. DOI:10. 1021/bc200258x.
  • 2Woods M, Kovacs Z, Kiraly R, et al. Solution dynamics and stabili- ty of lanthanide ( I ) (S) -2- (p-nitrobenzyl) DOTA complexes [ J ]. Inorg Chem, 2004, 43(9) : 2845-2851.
  • 3Taieb D, Garrigue P, Bardis M, et al. Application and dosimetric requirements for Gallium-68-1abeled somatostatin analogues in targe- ted radionuclide therapy for gastroenteropancreatic neuroendocrine tumors[J]. PET Clin, 2015, 10(4): 477-486. DOI:10.1016/j. cpet.2015.06.001.
  • 4Liu S, Edwards DS. Bifunctional chelators for therapeutic lantha- nide radiopharmaceuticals[ J]. Bioconjug Chem, 2001, 12(1) : 7- 34. DOI: 10.1021/bc000070v.
  • 5Dijkgraaf I, Liu S, Kruijtzer JA, et al. Effects of linker variation on the in vitro and in vivo characteristics of an 111 In-labeled RGD pep- tide [ J ]. Nucl Med Biol, 2007, 34( 1 ) : 29-35.DOI : 10.1016/j.nu- cmedbio.2006.10.006.
  • 6Parry JJ, Kelly TS, Andrews R, et al. In vitro and in vivo evalua- tion of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues con-taining different amino acid linker moieties [ J]. Bioconjug Chem, 2007, 18(4) : 1110-1117. DOI:10.1021/bc0603788.
  • 7Benetollo F, Bomhieri G, Calabi L, et al. Structural variations across the lanthanide series of macrocyclic DOTA complexes: in- sights into the design of contrast agents for magnetic resonance ima- ging[J]. Inorg Chem, 2003, 42(1): 148-157. DOI:10.1021/ ic025790n.
  • 8Woods M, Kovacs Z, Zhang S, et al. Towards the rational design of magnetic resonance imaging contrast agents : isolation of the two co- ordination isomers of lanthanide DOTA-type complexes[ J l. Angew Chem Int Ed Engl, 2003, 42 (47) : 5889-5892. DOI: 10. 1002/ anie.200352234.
  • 9Heppeler A, Froidevaux S, Macke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated in- ternal radiotherapy [J ]. Chem-Eur J, 1999, 5 (5) : 1974-1981. DOI : 10. 1002/( SICI ) 1521-3765 ( 19990702 ) 5 : 7 < 1974 : : AID- CHEM 1974> 3.0. CO ; 2-X.
  • 10Liu S, He Z, Hsieh WY, et al. Synthesis, characterization, and X- ray crystal structure of In (DOTA-AA) (AA = p-aminoanilide) : a model for 11tin-labeled DOTA-biomolecule conjugates [ J]. Inorg Chem, 2003, 42(26): 8831-8837. DOI: 10.1021/ic0349914.

二级参考文献16

  • 1赵德善,乔振华,张伟华,李险峰,刘晨,段炼,王进,胡光,李思进,张承刚.^(99)Tc^m-奥曲肽显像在淋巴瘤诊断中的应用[J].中华核医学杂志,2007,27(4):224-226. 被引量:4
  • 2Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system[ M]. Lyon: IARC, 2010.
  • 3Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neu- roendoerine tumors[J]. J Nucl Med, 2010, 51(3) : 353-359.
  • 4Haug AR, Auemhamrner C J, Wangler B, et al. 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin recep- tor-mediated radionuclide therapy in patients with well-differentia- ted neureendocrine tumors[J]. J Nucl Med, 2010, 51(9) : 1349- 1356.
  • 5Yao JC, Hassan M, Phan A, et al. One hundred years after "car- cinoid" : epidemiology of and prognostic factors for neuroendocfine tumors in 35 825 cases in the United States [ J ]. J Clin Oncol, 2008, 26(18) : 3063-3072.
  • 6Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system[ M]. Lyon: IARC, 2010.
  • 7Reubi JC. Peptide receptors as molecular targets for cancer diagno- sis and therapy[J]. Endocr Rev, 2003, 24(4) : 389-427.
  • 8Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consen- sus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled so- matostatin analogs[J]. Neureendocrinology, 2009, 90(2): 220- 226.
  • 9Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [^111In-DTPA-D-Phel ]- and [^1231- Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients[J]. EurJ Nucl Med, 1993, 20(8): 716-731.
  • 10Decfistoforo C, Mather SJ, Cholewinski W, et al. ^99Tc^m-EDDA/ HYNIC-TOC: a new ^99Tc^m-labelled radiopharmaceutical for ima- ging somatostatin receptor-positive turnouts ; first clinical results and intra-patient comparison with ^111In-labelled octreotide derivatives [J]. EurJ Nucl IVied, 2000, 27(9): 1318-1325.

共引文献20

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部